Is Imatinib Mesilate compatible with breastfeeding? Do we have alternatives for Imatinib Mesilate?

Imatinib Mesilate

September 5, 2014 (High Risk)

Inhibitor of tyrosine kinase that is used for treatment of Leukemia and some types of cancer.

Excretion intro breast milk is very low, with no problems reported among breastfed infants from treated mothers.

Concentration in the mother's milk decreases to one half after 9 hours from the last dose which is a property that could be taken advantage of to minimize the dose transfer to the infant if stopping breastfeeding is not desired.

If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, breastfeeding should be stopped for 10 half-lives (T ½).

It means wait 16 days after the last dose before resuming breastfeeding.

Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.

Alternatives

We do not have alternatives for Imatinib Mesilate.

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Synonyms

  • Иматиниба Мезилат
  • イマチニブメシル酸塩

Drug trade names

References

  1. Anderson PO. Cancer Chemotherapy. Breastfeed Med. 2016Abstract Full text (link to original source) Full text (in our servers)
  2. Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges. 2015Abstract Full text (link to original source) Full text (in our servers)
  3. PDR.net. Imatinib. Drug Summay. 2014 Full text (link to original source) Full text (in our servers)
  4. Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V; Society of Obstetricians and Gynaecologists of Canada. Cancer chemotherapy and pregnancy. J Obstet Gynaecol Can. 2013Abstract Full text (link to original source) Full text (in our servers)
  5. Pistilli B, Bellettini G, Giovannetti E, Codacci-Pisanelli G, Azim HA Jr, Benedetti G, Sarno MA, Peccatori FA. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013Abstract
  6. Jiang Q, Jiang B, Chen SS, Jiang H, Qin YZ, Lai YY, Shi HX, Huang XJ. [Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors]. Zhonghua Xue Ye Xue Za Zhi. 2012Abstract
  7. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011Abstract
  8. Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, Yorulmaz H, Tunali A. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet. 2009Abstract
  9. Kronenberger R, Schleyer E, Bornhäuser M, Ehninger G, Gattermann N, Blum S. Imatinib in breast milk. Ann Hematol. 2009Abstract
  10. Gambacorti-Passerini CB, Tornaghi L, Marangon E, Franceschino A, Pogliani EM, D'Incalci M, Zucchetti M. Imatinib concentrations in human milk. Blood. 2007Abstract
  11. Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007Abstract
  12. Garderet L, Santacruz R, Barbu V, van den Akker J, Carbonne B, Gorin NC. Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica. 2007Abstract
  13. EMEA. Imatinib. Ficha técnica. 2006 Full text (in our servers)